Annals of Surgical Oncology

, Volume 19, Issue 5, pp 1508–1516

Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer


    • Department of Gynecology and Obstetrics and Breast UnitGoethe University
  • Gunter von Minckwitz
    • German Breast Group
  • Elefhterios P. Mamounas
    • Aultman Cancer Center
  • David Cameron
    • Edinburgh Cancer Research CenterUniversity of Edinburgh
  • Lisa A. Carey
    • Division of Hematology-OncologyUniversity of North Carolina
  • Massimo Cristofanilli
    • Department of Medical OncologyFox Chase Cancer Center
  • Carsten Denkert
    • Institute of PathologyUniversity Hospital Charité
  • Wolfgang Eiermann
    • Women’s HospitalRed Cross Clinics
  • Michael Gnant
    • Department of SurgeryMedical University of Vienna
  • Jay R. Harris
    • Department of Radiation OncologyDana-Farber Cancer Institute, Harvard Medical School
  • Thomas Karn
    • Department of Gynecology and Obstetrics and Breast UnitGoethe University
  • Cornelia Liedtke
    • Department of Gynecology and ObstetricsUniversity Hospital Muenster
  • Davide Mauri
    • Department of Medical OncologyGeneral Hospital of Lamia
  • Roman Rouzier
    • Department of Obstetrics and GynecologyHôpital Tenon
  • Eugen Ruckhaeberle
    • Department of Gynecology and Obstetrics and Breast UnitGoethe University
  • Vladimir Semiglazov
    • N.N. Petrov Research Institute of Oncology
  • W. Fraser Symmans
    • Department of PathologyThe University of Texas MD Anderson Cancer Center
  • Andrew Tutt
    • Breakthrough Breast Cancer Research UnitGuy’s Hospital Campus, King’s College London School of Medicine
  • Lajos Pusztai
    • Department of Medical OncologyThe University of Texas MD Anderson Cancer Center
Breast Oncology

DOI: 10.1245/s10434-011-2108-2

Cite this article as:
Kaufmann, M., von Minckwitz, G., Mamounas, E.P. et al. Ann Surg Oncol (2012) 19: 1508. doi:10.1245/s10434-011-2108-2


The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s, NST was shown to substantially improve breast-conserving surgery rates and was first typically used for patients with inoperable locally advanced or inflammatory breast cancer. Investigators have since also used NST as an in vivo test for chemosensitivity by assessing pathologic complete response. Today, by using pathologic response and other biomarkers as intermediate end points, results from trials of new regimens and therapies that use NST are aimed to precede and anticipate the results from larger adjuvant trials. In 2003, a panel of representatives from various breast cancer clinical research groups was first convened in Biedenkopf to formulate recommendations on the use of NST. The obtained consensus was updated in two subsequent meetings in 2004 and 2006. The most recent conference on recommendations on the use of NST took place in 2010 and forms the basis of this report.

Copyright information

© Society of Surgical Oncology 2011